Feature|Articles|June 9, 2026

Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner

With more than $43 billion committed in five months, the pharma industry isn't just licensing from China, it's restructuring where global drug discovery begins.

The pace and scale of the pharma industry’s turn toward China in early 2026 is difficult to overstate, with more than $43 billion in licensing commitments in just five months. What is currently unfolding can be described as a structural realignment of where the global drug industry sources its innovation, and its terms.